MedTrace Logo

A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease

NCT05476783 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2026-05-06

Study results available
· View outcomes & findings →

Summary

This is an open-label long term extension study for participants with Alzheimer's disease (AD) who have completed Protocol TB006AD2102 (lead-in study) or participants who would have been eligible for the lead-in study but were not enrolled (de novo). The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TB006. The total study duration for each participant will be up to 113 weeks.

Conditions

Interventions

DRUG

TB006

Clear to slightly opalescent, sterile solution for injection

Sponsors & Collaborators

  • TrueBinding, Inc.

    lead INDUSTRY

Principal Investigators

  • Alan K Jacobs, MD · TrueBinding, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-15
Primary Completion
2023-11-17
Completion
2023-11-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05476783 on ClinicalTrials.gov